Webinar

Development of a multiplex assay for prediction of immunotherapy response in metastatic melanoma patients

Event: Development of a multiplex assay for prediction of immunotherapy response in metastatic melanoma patients
Join Prof. Paolo Ascierto and Dr. Gabriele Madonna for an exclusive presentation during Melanoma Awareness Month.

 

Title: Development of a multiplex assay for prediction of immunotherapy response in metastatic melanoma patients

Date: May 18, 2022 | 3:00 PM CEST

Speakers: 

Prof. Paolo Ascierto, Director of the Unit of Melanoma, National Tumor Institute G. Pascale, Naples, Italy

Dr. Gabriele Madonna, Health Researcher, National Tumor Institute G. Pascale, Naples, Italy

Abstract:

Melanoma is the most aggressive among all skin cancers and is responsible for high mortality rate. Combined immunotherapies have demonstrated a greater efficacy to boost the immune system of melanoma patients. However, the clinical decision on which combination to be used and which patients will benefit the most from it, remains a challenge. Understanding the immune context of patients’ tumor and the identification of reliable biomarker redouts will assist clinicians in their decision. We developed a multiplex immunohistochemistry assay to profile the tumor microenvironment of metastatic melanoma patients who responded or not to combined immunotherapy. We used LabSat®, an automated stainer based on Lunaphore’s microfluidic technology, to analyze the expression of PD-L1, CD8 and LAG-3. Our results provide first-time evidence of a different expression pattern of these markers between responder and non-responder melanoma patients.

 

At the end of the webinar, there will be a live Q&A session, giving the opportunity to ask your questions to our speakers. Not available? Register anyway and access the webinar on-demand.

 

Register Now